Navigation Links
The Female Health Company Schedules Conference Call to Discuss FDA Approval of FC2 Female Condom(R) for March 12, 2009

CHICAGO, March 11 /PRNewswire-FirstCall/ -- The Female Health Company (NYSE Amex: FHC) today announced that it will host an investor conference call to discuss the FDA's Approval of the FC2 Female Condom(R) on Thursday, March 12, 2009 at 11:00 a.m. Eastern Time (EDT). The Company announced its receipt of FDA approval for the FC2 Female Condom(R) in a news release earlier today.

Shareholders and other interested parties may participate in the conference call by dialing 800-860-2442 (international participants dial 412-858-4600) and asking to be connected to "The Female Health Company Conference Call," a few minutes before 11:00 a.m. EDT on March 12, 2009. A replay of the call will be available one hour after the call through 5:00 p.m. EDT on March 19, 2009 by dialing 877-344-7529 (international callers dial 412-317-0088) and entering the conference ID 428912.

About The Female Health Company

The Female Health Company, headquartered in Chicago, IL, manufactures and markets the FC Female Condom(R) (FC1) and the FC2 Female Condom(R) (FC2), which are primarily distributed by public health organizations and donor groups in over 90 developing countries around the world. Globally, the Female Condoms are available in various programs in 116 countries. The Company owns certain worldwide rights to FC1, including patents that have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, the European Patent Convention, the People's Republic of China, Canada, South Korea and Australia. FC1 and FC2 are the only available FDA-approved products controlled by a woman that offer dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy.

For more information about the Female Health Company, visit the Company's website at and If you would like to be added to the Company's e-mail alert list, please send an email to

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical fact are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release include expectations regarding the cost of and demand for FC2. These statements are based upon the Company's current plan and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information of future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communication and Securities and Exchange Commission filings, including the Company's Form 10-K for the fiscal year ended September 30, 2008. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

    Contacts:  William R. Gargiulo, Jr.  231-526-1244
               Donna Felch, CFO          312-595-9123

SOURCE The Female Health Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Female Health Company Receives FDA Approval for FC2 Female Condom(R)
2. Female genital mutilation among Israels Negev Bedouins has virtually disappeared -- BGU study
3. The Female Health Company Expands and Extends Its Stock Repurchase Program
4. The Female Health Company Reports First Quarter Operating Results, as Gross Profit Margins Widen on Increasing Sales of FC2 Female Condom(R)
5. Female Hormones Deter Salt-Sensitive Hypertension
6. The Female Health Company Schedules First Quarter Conference Call for February 10, 2009
7. Living with females extends the reproductive life of the male mouse, says Penn veterinary researcher
8. FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable
9. Surprising Results on Smoking Research Hispanic Versus White Female Smokers
10. Latin American and U.S. Latina Women Unite to Demand Access to the Female Condom
11. The Female Health Company Schedules Year End FY2008 Conference Call for December 1, 2008
Post Your Comments:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... gatherings where preparing the perfect dish and pleasing the palates of attendees is ... or bringing a dish to a seasonal get-together, give these recipes a try ...
(Date:11/25/2015)... Vegas, NV (PRWEB) , ... November 25, 2015 , ... ... invites patients to learn more about hair loss treatment with the Capillus272™ Pro laser ... an effective solution for thicker and fuller hair, without the need for surgery, prescription ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... and athletic programs, launches new Wimbledon Athletics Facebook page to educate ... athletes for unsuspected cardiac abnormalities. About 2,000 people under the age of 25 ...
(Date:11/25/2015)... ... 25, 2015 , ... SCOTTSDALE, AZ) - Today, Dr. ... both surgical and non-surgical treatments, announced the expansion of his private practice capabilities ... , Highly trained and nationally recognized for his natural approach, Dr. Todd ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Trovagene, Inc. ... diagnostics, today announced that Chief Executive Officer Antonius Schuh, ... the 27 th Annual Piper Jaffray Healthcare Conference. ... at the New York Palace Hotel in ... at 1:30 p.m. EST. Mr. Schuh will be available ...
(Date:11/25/2015)... 25, 2015 Endo International plc (NASDAQ: ENDP ... , President and CEO, will discuss corporate updates at the ... New York on Wednesday, December 2, 2015 ... on Investor Relations, and then the link to the event. ... start time to visit the site and download any streaming ...
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
Breaking Medicine Technology: